Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax after TKI to target persisting stem cells in CML
2022-003069-39Phase 2Active
- Sponsor
- Friedrich Schiller University Jena
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic myelogenous leukemia (CML), sponsored by Friedrich Schiller University Jena. Primary endpoint: Reduction of BCR::ABL1 stem cells in bone marrow. Started Jan 2023; status: active.
02
Drugs
venetoclax
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2022-003069-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003069-39.